Abstract 1857P
Background
The COVID-19 pandemic has been closely associated with a decline in mental health. The goal of this study was to identify the degree of distress of cancer patients before and after the pandemic and to find out if COVID-19 worsened the mental health of cancer patients.
Methods
A self-rated survey was conducted for 2 groups of patients at The Todua Clinic, Tbilisi, Georgia twice: at the peak of pandemic and again 6 months after the pandemic. Study included adult cancer patients, with solid tumors, over 18 years of age, receiving chemotherapy, being able to understand and answer the questions in written English. Event Scale-Revised (IES-R) test was implemented to measure Post-Traumatic Stress Disorder (PTSD). Total IES-R score of 33 or over signifies the likely presence of PTSD.
Results
Study enrolled total of 195 patients, 103 patients - during and 92 - after the pandemic. 3 independent and 5 dependent variables were created. Independent variables were: 1. IES-R score ≥24 ( y=1 if score ≥ 24, y=0 if score ≤ 24); 2. IES-R score≥ 33 (y=1 if score ≥ 33, y=0 if score ≤ 33); 3. IES-R score 37 (y= 1 if score ≤ 37, y=0 f score ≤ 37). Five dependent variables were: time, type of disease, stage, sex, and marital status. We created 3 regression models with independent and dependent variables (model 1: independent variable was IES-R score ≥24, model 2 independent variable was - IES-R score ≥ 33, model 3 IES-R score ≥ 33). We observed improvement in IES-R scores in the post-pandemic period: In model 1 - results improved by 20%, In model 2 - 16%, and in model 3 – 14%. Female and married individuals had better results in both periods. We calculated the data and observed that all dependent variables other than the disease type and the disease stage had a significant impact on IES-R scores.
Conclusions
Our findings showed a significant difference in IES-R scores in patients before and after the COVID-19 pandemic, with notable improvement in the post-COVID period. We also observed that sex, disease stage, marital status, and disease stage affected IES-R scores. We conclude that COVID-19 worsened the mental health of cancer patients. Our study highlighted the need for efforts to better integrate psychosocial support into cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05